PDF herunterladen
Thromb Haemost 1980; 43(01): 041-044
DOI: 10.1055/s-0038-1650008
Original Article
Schattauer GmbH Stuttgart

Increased Ristocetin-Cofactor in Acute Myocardial Infarction: a Component of the Acute Phase Reaction

Mircea P Cucuianu
The Medical Clinic No. 1 Cluj-Napoca, Romania
,
Ileana Missits
The Medical Clinic No. 1 Cluj-Napoca, Romania
,
Nour Olinic
The Medical Clinic No. 1 Cluj-Napoca, Romania
,
Stefan Roman
The Medical Clinic No. 1 Cluj-Napoca, Romania
› Institutsangaben
Weitere Informationen

Publikationsverlauf

Received 04. November 1979

Accepted 24. Dezember 1979

Publikationsdatum:
13. Juli 2018 (online)

  als PDF herunterladen  Lizenzen und Reprints

Summary

When compared to the values obtained in healthy normal-weight, normolipemic controls, the plasma level of ristocetin-cofactor (VIII: R-cof.) was found to be much higher in patients with acute myocardial infarction and in postoperative conditions (4–5 days after a major surgical intervention). A lesser increase of VIII: R-cof. was noted in atherosclerotic patients without acute occlusive accidents and no significant changes of this plasma factor could be observed in hyperlipemic subjects without obvious clinical atherosclerosis. Serial studies emphasized a tendency towards normalization of plasma VIII: R-cof. as the acute phenomena of a myocardial infarction subsided. The above mentioned data suggest that the high levels of VIII: R-cof. recorded in myocardial infarction are mainly caused by a systemic acute phase reaction and to a lesser extent by endothelial damage. Delayed clearance of VIII: R-cof. subsequent to a hepatic dysfunction or to a modified pattern of protein metabolism during the above mentioned acute phase reaction might also contribute to the high level of this plasma factor.

Keywords

Myocardial infarction - Acute phase reaction - Ristocetin-cofactor
 

  • References

  • 1 Holmberg J, Nilsson IM. AHF-related protein in clinical praxis. Scand J Haematol 1974; 12: 221-231
    PubMedGoogle Scholar
  • 2 Ekberg M, Nilsson IM. Factor VIII and glomerulonephritis. Lancet 1975; 1: 111-113
    PubMedGoogle Scholar
  • 3 Bensoussan D, Levy-Toledano S, Passa P, Caen J, Canivet J. Platelet hyperaggregation and increased plasma level of von Willebrand factor in diabetics with retinopathy. Diabetologia 1975; 11: 307-312
    CrossrefPubMedGoogle Scholar
  • 4 Boneu B, Durand D, Counillon F, Charlet JP, Bierme R, Sue JD. Increased level of factor VIII complex in severe arterial hypertension. Haemostasis 1978; 7: 332-338
    PubMedGoogle Scholar
  • 5 Fuster V, Bowie EJ W. The von Willebrand pig as a model for atherosclerosis research. Thrombos Haemostas Stuttg. 1978; 39: 322-327
    PubMedGoogle Scholar
  • 6 Cucuianu M, Vasile V, Popescu TA, Opincaru A, Crisnic I, Tapalaga D. Clinical studies concerning factor XIII; with special reference to hyperlipemia. Thrombos Diathes Haemorrh Stuttg. 1973; 30: 480-493
    PubMedGoogle Scholar
  • 7 Astrup T, Brakman P, Nissen U. The estimation of fibrinogen. A revision. Scand J clin Lab Invest 1965; 17: 57-65
    CrossrefPubMedGoogle Scholar
  • 8 Richterich R. Enzymopathologie, . Springer Verlag, Berlin – Göttingen – Heidelberg: 1958: 560-568
    Google Scholar
  • 9 Cucuianu M, Opincaru A, Tapalaga D. Similar behaviour of lecithin: cholesterol acyltransferase and pseudocholinesterase in liver disease and hyperlipoproteinemia. Clin Chim Acta 1978; 85: 73-79
    CrossrefPubMedGoogle Scholar
  • 10 Bockendahl H, Ammon R. Cholinesterases. in Bergmeyer HU. (Ed) Methods of Enzymatic Analysis, Second Edition Academic Press, New York – London: 1965: 771-775
    Google Scholar
  • 11 Weiss HJ, Rogers I, Brand H. Defective ristocetin aggregation in von Willebrand’s disease and its correction by factor VIII. J Clin Invest 1973; 52: 2697-2707
    CrossrefPubMedGoogle Scholar
  • 12 Allain JP, Cooper HA, Wagner RH, Brinkhous KM. Platelets fixed with paraformaldehyde: A new reagent for assay of von Willebrand factor and platelet aggregating factor. J Lab Clin Med 1975; 85: 318-328
    PubMedGoogle Scholar
  • 13 Ceratz JD, Tidwell RR, Brinkhous KM, Mohammad SF, Dann O, Loewe H. Specific inhibition of platelet agglutination and aggregation by aromatic amidino compounds. Thrombos Haemostas Stuttg. 1978; 39: 411-425
    PubMedGoogle Scholar
  • 14 Green D, Potter E. Platelet bound ristocetin aggregation factor in normal subjects and patients with von Willebrand’s disease. J Lab Clin Med 1976; 87: 976-986
    PubMedGoogle Scholar
  • 15 Barzu O. Spectrophotometric assay of oxygen consumption in:. Fleischer S, Packer L. (Eds) Methods in Enzymology. Academic Press, New York: 1978. 54 485-498
    Google Scholar
  • 16 Barzu O, Dansoreanu M, Munteanu R, Ana A, Bara A. Standardized device for the assay of oxygen consumption adaptable to commercial photometers. Anal Biochem 1979; 101: 138-147
    PubMedGoogle Scholar
  • 17 Hoyer LW, De Los Santos RP, Hoyer JR. Antihaemophilic Factor Antigen. Localization in endothelial cells by immunofluorescent microscopy. J Clin Invest 1973; 52: 2737-2744
    CrossrefPubMedGoogle Scholar
  • 18 Jaffe EA, Hoyer LW, Nachman RL. Synthesis of antihaemophilic factor antigen by cultured human endothelial cells. J Clin Invest 1973; 52: 2757-2764
    CrossrefPubMedGoogle Scholar
  • 19 Grant K, Rodvien R, Mielke Jr CH. Altered factor VIII complexes in patients with acute respiratory insufficiency. Thrombos Haemostas Stuttg. 1978; 40: 326-334
    PubMedGoogle Scholar
  • 20 Nilsson IM. Von Willebrand Disease – Fifty years old. Acta Med Scand 1977; 201: 497-508
    PubMedGoogle Scholar
  • 21 Egeberg O. Changes in the activity of antihaemophilic A factor (F VIII) and in the bleeding time associated with muscular exercise and adrenalin infusion. Scand J Clin Lab Invest 1963; 15: 539-549
    CrossrefPubMedGoogle Scholar
  • 22 Eyster ME, Ballard JO, Pager D. Comparison of factor VIII levels after adrenalin in classic haemophilia and von Willebrand’s disease. Thrombos Haemostas Stuttg. 1978; 39: 657-662
    PubMedGoogle Scholar
  • 23 Wocial B, Sznajderman M, Januszewicz W, Raczynski J. The urinary excretion of 3-methoxy-4-hydroxyphenylglycol in acute myocardial infarction. Clin Chim Acta 1979; 95: 517-520
    CrossrefPubMedGoogle Scholar
  • 24 Green AJ, Ratnoff OD. Elevated antihaemophilic factor procoagulant activity and antihaemophilic factor like antigen in alcoholic cirrhosis of the liver. J Lab Clin Med 1974; 83: 189-197
    PubMedGoogle Scholar
  • 25 Maisonneuve P, Sultan Y. Modification of factor VIII complex properties in patients with liver disease. J Clin Pathol 1977; 30: 221-227
    CrossrefPubMedGoogle Scholar
  • 26 Blomhoff JP, Skrede S, Ritland S. Lecithin-cholesterol acyltransferase and plasma proteins in liver disease. Clin Chim Acta 1974; 53: 197-207
    CrossrefPubMedGoogle Scholar
  • 27 Biland L, Duckert F, Prisender S, Nyman D. Quantitative estimation of coagulation factors in liver disease. The diagnostic and prognostic value of factor XIII, factor V and plasminogen. Thrombos Haemostas Stuttg. 1978; 39: 646-656
    PubMedGoogle Scholar
  • 28 Ritland S, Blomhoff JP, Enger SC, Skrede S, Gjone E. The esterification of cholesterol in plasma after acute myocardial infarction. Scand J Clin Lab Invest 1975; 35: 181-187
    CrossrefPubMedGoogle Scholar
  • 29 Alkjaersig N, Fletcher AP, Lewis M, Ittyerah R. Reduction of coagulation factor XIII in patients with myocardial infarction, cerebral infarction and other thromboembolic disorders. Thrombos Haemostas Stuttg. 1977; 38: 863-873
    PubMedGoogle Scholar
  • 30 Doenicke A. Das Verhalten der Pseudocholinesterase im postoperativen Schock. In: Goede HW, Doenicke A, Altland K. (Eds.) Pseudocholinesterasen, Pharmakogenetik-Biochemie-Klinik, . Springer Verlag, Berlin – Heidelberg – New York: 1967: 146-151
    Google Scholar
  • 31 Werner M. Serum protein changes during the acute phase reaction. Clin Chim Acta 1969; 25: 299-305
    CrossrefPubMedGoogle Scholar
  • 32 Gormsen J. Fibrinolytic activity. Inhibition of plasminogen activation. Acta Med Scand 1962; 172: 657-663
    PubMedGoogle Scholar
  • 33 Constantino M, Merskey C, Kudzma DJ, Zucker MB. Increased activity of vitamin K dependant clotting factors in human hyperlipoproteinemia; association with cholesterol and triglyceride levels. Thrombos Haemostas Stuttg. 1977; 38: 465-474
    PubMedGoogle Scholar
  • 34 Cucuianu M, Stef C, Zdrenghea D, Popescu O. In vitro effect of p. chlormercuribenzoate upon dilute blood lysis time in hyperlipemia. Thrombos Haemostas Stuttg. 1979; 42: 929-944
    PubMedGoogle Scholar